BIOCRYST PHARMACEUTICALS, INC. (BCRX) Total liabilities 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) total liabilities at each fiscal year-end, per SEC filings.
$633.3MFY2025 · since FY2016: $88.3M → $633.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $633.3M | -34.5% |
| FY2024 | $966.4M | -0.6% |
| FY2023 | $972.5M | +15.1% |
| FY2022 | $844.6M | +21.5% |
| FY2021 | $695.1M | +96.4% |
| FY2020 | $354.0M | +158.3% |
| FY2019 | $137.0M | +40.4% |
| FY2018 | $97.6M | +3.3% |
| FY2017 | $94.5M | +7.1% |
| FY2016 | $88.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Gross marginBCRX Operating incomeBCRX Operating marginBCRX Operating cash flowBCRX Free cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Shareholders’ equityBCRX overview →